BACKGROUND/AIMS: Insulin-like growth factor-1 (IGF-1) is a mitogenic and anti-apoptotic factor, mainly produced by the liver, which regulates cell proliferation. Most serum IGF-1s are bound with IGF-1BP3. Plasma IGF-1 values are positively related to cancer risk (breast, colon, and lung cancer) and seem to have a prognostic significance in prostatic cancer. The aim of this study is to investigate the relationship between IGF-1, IGF-1BP3 and gastric cancer. METHODOLOGY: IGF-1 and IGF-1BP3 serum levels were measured in 26 consecutive patients (M/F = 15/11, mean age 65 yrs) with histologically proven gastric adenocarcinoma from January 1999 to December 2000. Blood samples were collected at baseline, before surgery with radical intent (total and subtotal gastrectomies + D2 lymphadenectomy), and then at 14th and 50th postoperative days. These values were compared to a control group of healthy people. RESULTS: At baseline was observed a significant increase of IGF-1 serum levels in cancer patients versus control group (p < 0.001). All gastric cancer patients showed IGF-1 over normal limits. After surgery there was a significant decrease of IGF-1 levels (14th day vs. baseline, p = 0.001) that was still present in late postoperative period (50th day). At baseline IGF-1 values were not related to tumor extension or nodal involvement status. Otherwise in postoperative period IGF-1 significantly decreased in earlier stages (N0; T < or = 2) but not in more advanced ones (N+; T > 2). At baseline, IGF-1BP3 values were increased compared to control group but did not significantly decrease after surgery. CONCLUSIONS: IGF-1 values in gastric cancer patients are increased compared to control group, without stratification for stage and nodal status. Moreover radical surgery, with complete tumor ablation, induces a significant decrease in IGF-1 levels, without reach normal limits. Besides at baseline abnormally higher IGF-1BP3 values were observed, suggesting an alteration in IGF-1 and IGF-1BP3 system.
BACKGROUND/AIMS: Insulin-like growth factor-1 (IGF-1) is a mitogenic and anti-apoptotic factor, mainly produced by the liver, which regulates cell proliferation. Most serum IGF-1s are bound with IGF-1BP3. Plasma IGF-1 values are positively related to cancer risk (breast, colon, and lung cancer) and seem to have a prognostic significance in prostatic cancer. The aim of this study is to investigate the relationship between IGF-1, IGF-1BP3 and gastric cancer. METHODOLOGY:IGF-1 and IGF-1BP3 serum levels were measured in 26 consecutive patients (M/F = 15/11, mean age 65 yrs) with histologically proven gastric adenocarcinoma from January 1999 to December 2000. Blood samples were collected at baseline, before surgery with radical intent (total and subtotal gastrectomies + D2 lymphadenectomy), and then at 14th and 50th postoperative days. These values were compared to a control group of healthy people. RESULTS: At baseline was observed a significant increase of IGF-1 serum levels in cancerpatients versus control group (p < 0.001). All gastric cancerpatients showed IGF-1 over normal limits. After surgery there was a significant decrease of IGF-1 levels (14th day vs. baseline, p = 0.001) that was still present in late postoperative period (50th day). At baseline IGF-1 values were not related to tumor extension or nodal involvement status. Otherwise in postoperative period IGF-1 significantly decreased in earlier stages (N0; T < or = 2) but not in more advanced ones (N+; T > 2). At baseline, IGF-1BP3 values were increased compared to control group but did not significantly decrease after surgery. CONCLUSIONS:IGF-1 values in gastric cancerpatients are increased compared to control group, without stratification for stage and nodal status. Moreover radical surgery, with complete tumor ablation, induces a significant decrease in IGF-1 levels, without reach normal limits. Besides at baseline abnormally higher IGF-1BP3 values were observed, suggesting an alteration in IGF-1 and IGF-1BP3 system.
Authors: Y Min; Y Adachi; H Yamamoto; A Imsumran; Y Arimura; T Endo; Y Hinoda; C-T Lee; S Nadaf; D P Carbone; K Imai Journal: Gut Date: 2005-05 Impact factor: 23.059
Authors: Lidia Kędzierska; Anna Madej-Michniewicz; Natalia Marczuk; Barbara Dołęgowska; Teresa Starzyńska; Wojciech Błogowski Journal: Am J Transl Res Date: 2020-01-15 Impact factor: 4.060
Authors: Annika Steffen; José-Maria Huerta; Elisabete Weiderpass; H B As Bueno-de-Mesquita; Anne M May; Peter D Siersema; Rudolf Kaaks; Jasmine Neamat-Allah; Valeria Pala; Salvatore Panico; Calogero Saieva; Rosario Tumino; Alessio Naccarati; Miren Dorronsoro; Emilio Sánchez-Cantalejo; Eva Ardanaz; J Ramón Quirós; Bodil Ohlsson; Mattias Johansson; Bengt Wallner; Kim Overvad; Jytte Halkjaer; Anne Tjønneland; Guy Fagherazzi; Antoine Racine; Françoise Clavel-Chapelon; Tim J Key; Kay-Tee Khaw; Nick Wareham; Pagona Lagiou; Christina Bamia; Antonia Trichopoulou; Pietro Ferrari; Heinz Freisling; Yunxia Lu; Elio Riboli; Amanda J Cross; Carlos A Gonzalez; Heiner Boeing Journal: Int J Cancer Date: 2015-02-09 Impact factor: 7.396
Authors: P Bertuccio; D Praud; L Chatenoud; E Lucenteforte; C Bosetti; C Pelucchi; M Rossi; E Negri; C La Vecchia Journal: Br J Cancer Date: 2009-02-10 Impact factor: 7.640